Navigation Links
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
Date:11/19/2012

#160;Net margin for the second quarter of fiscal 2013 was 19.2%. 

EARNINGS PER SHARE.  The terms of the convertible note issued to KKR provides KKR with the ability to participate in any Excess Cash Dividend(2).  Therefore, the calculation of basic EPS has taken into consideration KKR's participating right effect of RMB0.01.  Basic and diluted earnings per ordinary share for the second quarter of fiscal 2013 were RMB0.34 ($0.05). 

LIQUIDITY.  As of September 30, 2012, the Company had cash and cash equivalents of RMB1,324.5 million ($210.7 million) compared to RMB794.3 million as of March 31, 2012.  The Company had total debt of RMB472.6 million ($75.2 million) as of September 30, 2012.  Operating cash flow for the quarter amounted to RMB142.5 million ($22.7 million).

First Half Fiscal 2013 Financial ResultsFor the first half of fiscal year 2013, total revenues increased by 31.1% to RMB243.8 million ($38.8 million) from RMB185.9 million in the prior year period.  The increase was largely attributable to the significant increase in new subscribers and the expansion of the Company's accumulated subscriber base to 274,705 subscribers.  Processing fees and storage fees grew by 33.6% and 24.0%, respectively.  Gross profit increased by 33.3% to RMB192.3 million ($30.6 million) from RMB144.3 million in the prior year period.  Operating income increased by 33.5% to RMB91.4 million ($14.6 million) from RMB68.5 million in the prior year period. Net income attributable to shareholders amounted to RMB55.8 million ($8.9 million).  Basic and diluted earnings per share attributable to ordinary shares were RMB0.75 ($0.12).  Net cash provided by operating activities in the first half of fiscal 2013 was RMB279.4 million ($44.5 million).

Ms. Zheng concluded, "Even though we recorded impressive performance in our operating markets, we are continuing our efforts to widen ma
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
2. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
3. China Biologic Products to Report Third Quarter 2012 Financial Results
4. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
5. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
6. Hawaii Tech Asia Takes Hawaii & US Entrepreneurs To China
7. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
8. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
9. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
10. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
11. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 ... ... research report, offering competitive market analysis and premium industry insights on the global ... challenges, based on a collective study of vivid market scenarios and analysis of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... press release is available in French . ... of matter, a quasi-three- dimensional electron crystal, in a ... of modern transistors. This discovery could have momentous implications ... number of transistors that can be inexpensively crammed onto ...
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial ... as guidance for net sales and,earnings per share (EPS) for ... -- Reported net sales of $1.978 billion and adjusted ... market leadership -- Achieved worldwide cardiac rhythm management (CRM) ...
... ... Development Company to Expedite Product ... Launches ... NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ...
Cached Biology Technology:McGill physicists find a new state of matter in a 'transistor' 2McGill physicists find a new state of matter in a 'transistor' 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... USA GEOLOGY ends 2012 with 23 ... locations, including Mercury; Naica Cave, Mexico; Diamantina, Brazil; the ... and Uummannaq Fjord, central West Greenland; the California arc; ... Iceland; the U.S. Sierra Nevada; Spain; New Zealand; Turkey; ...
... Mass. In the worldwide battle to curtail malaria, one ... developing world, drug after drug has fallen by the wayside ... artemisinin, derived from the sweet wormwood plant, Artemisia annua ... to produce (particularly when combined with other antimalarial medications to ...
... When different types of cells are transplanted with the ... system (CNS) trauma, what is the fate and function ... research aimed at answering this question by determining how ... embryonic fibroblasts, dendritic cells, bone marrow mononuclear cells (BMMNCs) ...
Cached Biology News:GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 2GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 3GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 4GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 5GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 6GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 7GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 8GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 9GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 10GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 11GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 12GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 13GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 14GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 15GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 16GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 17GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 18GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 19GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 20New whole plant therapy shows promise as an effective and economical treatment for malaria 2New whole plant therapy shows promise as an effective and economical treatment for malaria 3New whole plant therapy shows promise as an effective and economical treatment for malaria 4Cell Transplantation study investigates fate and function of cells transplanted to the CNS 2
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: